Inclusion Criteria:

          1. Signed informed consent form

          2. Age ≥ 18 years

          3. Recurrent or persistent EOC (epithelial ovarian, fallopian tube or primary peritoneal
             carcinoma)

          4. Have archival tissue or willingness to undergo a tumor biopsy

          5. Have measurable disease

          6. Have had one prior taxane-platinum-based chemotherapeutic regimen

          7. Have had a treatment-free interval following platinum-based therapy of less than 12
             months, have progressed during platinum-based therapy, or had persistent disease after
             a platinum-based regimen

          8. Have received hormonal therapy

          9. ECOG Performance Status of 0 to 1

         10. Ability to take oral medications

         11. HIV, HTLV-1, HBV, and HCV negative

         12. Adequate organ and bone marrow function as defined by study-specified laboratory tests

         13. Normal blood coagulation parameters

         14. Life expectancy greater than 16 weeks

         15. Must use acceptable form of birth control through the study and for 28 days after
             final dose of study drug

         16. Willing and able to comply with study procedures

        Exclusion Criteria:

          1. Prior therapy with an anti-CTLA-4 antibody or PARP inhibitor

          2. Active infection requiring antibiotics

          3. Active autoimmune disease

          4. Active and uncontrolled intercurrent illness

          5. History of other cancers within the past 5 years

          6. Systemically active steroid use

          7. Receiving systemic chemotherapy or radiotherapy within 4 weeks prior to the first dose
             of study drug

          8. Use of ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin,
             clarithromycin and nelfinavir

          9. Requirement for chronic parenteral hydration/nutrition

         10. Vaccination with live attenuated vaccine within 1 month prior to first dose of study
             drug

         11. Patients with untreated brain metastases, treated brain metastases that are not
             stable, leptomeningeal disease, or seizures uncontrolled with standard medical therapy

         12. Patients with myelodysplastic syndrome/acute myeloid leukaemia

         13. History of diverticulitis

         14. History of bleeding disorder or diathesis.

         15. Serious or nonhealing wound, ulcer, bone fracture, or osteonecrosis of the jaw

         16. Major surgical procedure within 28 days of study enrollment, or anticipated while on
             study.

         17. Pregnant or breast feeding woman